Company Update (NASDAQ:ECYT): Endocyte, Inc. Announces Updated Data on EC1456 and EC1169 at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that data featuring Endocyte’s SMDC, EC1456 will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 29 – June 2, 2015, in Chicago.

The EC1456 poster shows that EC1456 is generally well tolerated in previously treated cancer patients, with no treatment-related deaths, SAE’s, dose modifications, or Grade 4 toxicities on either schedule. There is also no evidence of cumulative or late emerging toxicity, thus far. Grade 1-2 toxicities include nausea, vomiting, stomatitis, abdominal pain, constipation, diarrhea, paresthesia, and fatigue. Cohort expansions are continuing at 4.5 mg/m2 (weekly schedule) and 2.5 mg/m2 (biweekly schedule). Anti-tumor activity with EC1456 is suggested by prolonged stable disease in FR+ patients: 11/20 patients had stable disease as their best study response. EC1456 shows a dose-dependent PK profile that has prolonged drug concentration above IC50 and is more favorable than the 1st generation SMDC, vintafolide. (Original Source)

Shares of Endocyte closed today at $6.03, up $0.0012 0.01%. ECYT has a 1-year high of $9.35 and a 1-year low of $5.01. The stock’s 50-day moving average is $6.15 and its 200-day moving average is $6.01.

On the ratings front, Endocyte has been the subject of a number of recent research reports. In a report issued on March 3, Wedbush analyst David Nierengarten reiterated a Buy rating on ECYT, with a price target of $12, which implies an upside of 99.3% from current levels. Separately, on March 2, Cantor Fitzgerald’s Daniel Brims reiterated a Buy rating on the stock and has a price target of $21.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, David Nierengarten and Daniel Brims have a total average return of 53.1% and -2.0% respectively. Nierengarten has a success rate of 61.8% and is ranked #10 out of 3600 analysts, while Brims has a success rate of 45.5% and is ranked #2978.

Endocyte Inc is a biopharmaceutical company. The Company is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts